Hodgkin Lymphoma News and Research RSS Feed - Hodgkin Lymphoma News and Research

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

The combination of two new drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. [More]
New report estimates global burden of cancer cases and deaths in 2015

New report estimates global burden of cancer cases and deaths in 2015

In 2015, there were an estimated 17.5 million cancer cases around the globe and 8.7 million deaths, according to a new report from the Global Burden of Disease Cancer Collaboration published online by JAMA Oncology. [More]
Study finds lack of improvement in health status of childhood cancer survivors

Study finds lack of improvement in health status of childhood cancer survivors

Long-term survivors of childhood cancer live longer thanks to improvements to cancer treatments, but a new study looking at three decades of therapy suggests patients do not report better health status. [More]
Cancers that cause huge impact on healthy years of life linked to smoking and alcohol

Cancers that cause huge impact on healthy years of life linked to smoking and alcohol

A new study finds eleven of the 15 cancers with the most impact on healthy years of life lost in the United States are closely-associated with two preventable risk factors: smoking and alcohol. [More]
NCCN publishes new resources to help patients understand treatment options for stomach cancer

NCCN publishes new resources to help patients understand treatment options for stomach cancer

This year, it is estimated that more than 26,000 people will be diagnosed with Stomach Cancer in the United States, with nearly one million new cases diagnosed worldwide each year. [More]
Study suggests targeting UNG enzyme may help treat non-Hodgkin's lymphoma

Study suggests targeting UNG enzyme may help treat non-Hodgkin's lymphoma

Researchers have discovered that an enzyme called uracil-DNA glycosylase (UNG) protects the ends of B cell chromosomes to facilitate the proliferation of these antibody-producing cells in response to infection. [More]
Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. [More]
Blood cancer is associated with considerably higher healthcare costs than other cancers

Blood cancer is associated with considerably higher healthcare costs than other cancers

Health economics studies, published today in The Lancet Haematology, report that the cost of treating blood cancers is twice that for treating other cancers. This is largely because they require more complex treatment regimens that necessitate longer hospital stays. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
Autologous stem cell transplant safe, effective for HIV-associated lymphoma patients

Autologous stem cell transplant safe, effective for HIV-associated lymphoma patients

New research published online today in Blood Journal of the American Society of Hematology (ASH), challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment. [More]
NCCN educational resources provide insight for patients with Mycosis Fungoides

NCCN educational resources provide insight for patients with Mycosis Fungoides

Mycosis Fungoides is a very rare form of lymphoma affecting approximately 1,000 people per year in the United States. [More]
Researchers find link between obesity and disease relapse in pediatric Hodgkin lymphoma patients

Researchers find link between obesity and disease relapse in pediatric Hodgkin lymphoma patients

Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents. [More]
Nivolumab drug shows better response rate in metastatic bladder cancer patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center. [More]
Initiatives to improve adolescent, young adult cancer outcomes justified

Initiatives to improve adolescent, young adult cancer outcomes justified

Analysis of the EUROCARE-5 data shows that although survival for adolescents and young adults with cancer has improved overall, the survival rates for certain malignancies still lag behind those for children. [More]
Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy. [More]
NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

NCCN publishes series of patient education materials for Non-Hodgkin's Lymphoma

It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016. The sixth leading cancer diagnosis in U.S. men and women, NHL has more than 30 sub-types, each featuring unique treatment choices and challenges. [More]
Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

New research from Roswell Park Cancer Institute shows that promising cancer drugs used in combination can have significant therapeutic impact on a particularly aggressive subtype of diffuse large B-cell lymphoma (DH-DLBCL) in preclinical studies. The researchers will present their findings at the American Association for Cancer Research (AACR) Annual Meeting 2016, to be held April 16-20 in New Orleans. [More]
MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in the most aggressive large B-cell lymphomas (DLBCL). By reducing NFκB signaling, miR-181a controls tumor cell proliferation and survival and could be the target of novel therapies. The study was published in the journal Blood. [More]
Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate. [More]
Advertisement